Wide Ranks

LYRA

Lyra Therapeutics, Inc.

0.1900

Top Statistics
Market Cap 12 M Forward PE -0.2011 Revenue Growth -64.20 %
Current Ratio 3.64 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 0.0580 Enterprise / Revenue -2.63 Price To Sales Trailing12 Months 8.45
Profitability
Profit Margins 0.00 % Operating Margins -4942.56 %
Balance Sheet
Total Cash 51 M Total Cash Per Share 0.7890 Total Debt 35 M
Total Debt To Equity 171.32 Current Ratio 3.64 Book Value Per Share 0.3150
All Measures
Short Ratio 121.00 % Message Board Id finmb_142648423 Shares Short Prior Month 2 M
Return On Equity -1.86 City Watertown Uuid e0a4f15e-34ef-3087-b120-b47efafe701f
Previous Close 0.1983 First Trade Date Epoch Utc 1 B Book Value 0.3150
Beta -0.0360 Total Debt 35 M Volume 1 M
Price To Book 0.6032 Fifty Two Week Low 0.1630 Total Cash Per Share 0.7890
Total Revenue 1 M Shares Short Previous Month Date 1 B Target Median Price 1.25
Max Age 86400 Recommendation Mean 2.60 Sand P52 Week Change 0.3133
Operating Margins -4942.56 % Target Mean Price 1.25 Net Income To Common -97612000
Short Percent Of Float 0.0453 Implied Shares Outstanding 65 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 3 M Average Volume10days 3 M
Total Cash 51 M Next Fiscal Year End 1 B Revenue Per Share 0.0230
Held Percent Insiders 0.0066 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 0.1983 Target Low Price 0.5000
Gmt Off Set Milliseconds -18000000 Fifty Day Average 0.2385 Open 0.1924
Free Cashflow -45860500 State MA Dividend Yield 0.00 %
Return On Assets -0.4229 Time Zone Short Name EST Trailing Eps -1.49
Day Low 0.1839 Address1 480 Arsenal Way Shares Outstanding 65 M
Price Hint 4 Target High Price 2.00 Website https://lyratherapeutics.com
52 Week Change -0.9426 Average Volume 1 M Forward Eps -0.7400
Recommendation Key hold Compensation As Of Epoch Date 1 B Quick Ratio 345.20 %
Is_sp_500 False Regular Market Day High 0.2068 Profit Margins 0.00 %
Debt To Equity 171.32 Fifty Two Week High 6.79 Day High 0.2068
Shares Short 2 M Regular Market Open 0.1924 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue -2.63 Revenue Growth -64.20 %
Shares Percent Shares Out 0.0363 Operating Cashflow -77717000 Currency USD
Time Zone Full Name America/New_York Market Cap 12 M Is_nasdaq_100 False
Zip 02472 Quote Type EQUITY Industry Biotechnology
Long Name Lyra Therapeutics, Inc. Regular Market Day Low 0.1839 Held Percent Institutions 0.5979
Current Price 0.1900 Enterprise To Ebitda 0.0580 Financial Currency USD
Current Ratio 3.64 Industry Disp Biotechnology Number Of Analyst Opinions 2
Country United States Float Shares 41 M Two Hundred Day Average 1.73
Enterprise Value -3865047 Price To Sales Trailing12 Months 8.45 Forward PE -0.2011
Regular Market Volume 1 M Ebitda -67039000 Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases.

It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration.

The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps.

It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand.

The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018.

Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.